Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial

Journal of Bone and Mineral Research, 02/22/2013

Data on treatment of glucocorticoid–induced osteoporosis (GIO) in men are scarce. In this 18–month trial in men with GIO, teriparatide showed larger improvements in spinal BMD, microstructure, and finite element (FE)–derived strength than risedronate.

Print Article Summary Cat 2 CME Report